Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
200 hedge funds and large institutions have $5.53B invested in Mirati Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 85 increasing their positions, 49 reducing their positions, and 18 closing their positions.
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
73% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 49
47% more capital invested
Capital invested by funds: $3.76B → $5.53B (+$1.77B)
16% more funds holding
Funds holding: 173 → 200 (+27)
8% less call options, than puts
Call options by funds: $46.5M | Put options by funds: $50.5M
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$45.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$31.6M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$25M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$19.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$68.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$53.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$45.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$33.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$22.7M |
MRTX Hedge Fund Activity: Q2 2020 in Review
200 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2020, worth a combined $5.53B — up 47% from $3.76B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MRTX positions and 18 closed out — a net gain of 28 holders — while 85 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $45.7M. The largest seller was Fidelity Investments, cutting an estimated $68.1M.
- 200 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2020, up from 173 in Q1 2020.
- Funds reported $5.53B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2020, up 47% quarter-over-quarter.
- 46 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2020 and 18 closed out, a net change of +28 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $45.7M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2020 was Fidelity Investments, an estimated $68.1M sold.
Based on aggregated 13F filings for Q2 2020.